Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 320.37M | 338.69M | 320.37M | 280.98M | 282.13M | 224.30M |
Gross Profit | 4.77M | 39.27M | 4.64M | 51.99M | 99.70M | 73.19M |
EBITDA | -12.31M | 28.42M | -22.15M | 35.72M | 83.35M | 58.55M |
Net Income | -51.44M | -19.56M | -51.44M | 7.77M | 47.26M | 31.34M |
Balance Sheet | ||||||
Total Assets | 76.29M | 756.58M | 689.09M | 575.78M | 595.04M | 375.98M |
Cash, Cash Equivalents and Short-Term Investments | 4.38M | 68.28M | 95.71M | 37.53M | 136.30M | 17.21M |
Total Debt | 8.84M | 94.12M | 113.66M | 21.22M | 18.00M | 37.43M |
Total Liabilities | 38.93M | 399.33M | 307.86M | 154.10M | 173.87M | 198.31M |
Stockholders Equity | 37.35M | 357.24M | 381.23M | 421.68M | 421.17M | 177.66M |
Cash Flow | ||||||
Free Cash Flow | -16.41M | 2.43M | -20.25M | -69.64M | -16.61M | 8.86M |
Operating Cash Flow | 36.48M | 89.40M | 36.48M | 5.46M | 57.35M | 49.48M |
Investing Cash Flow | -59.51M | -91.02M | -59.51M | -78.44M | -80.84M | -42.56M |
Financing Cash Flow | 84.55M | -25.32M | 84.55M | -26.87M | 130.93M | -6.73M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | CHF4.35B | 36.20 | 8.87% | 1.20% | 4.84% | 7.45% | |
75 Outperform | $4.10B | 24.50 | 18.36% | 4.52% | 1.82% | 39.11% | |
73 Outperform | CHF1.04B | 7.99 | 29.55% | 2.66% | 182.25% | ― | |
58 Neutral | CHF693.66M | ― | ― | 3.15% | 62.88% | ||
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% |
PolyPeptide Group AG has expanded its revolving credit facility by EUR 40 million to EUR 151 million, with an extension until March 2028, supported by UBS, Danske Bank, and Zürcher Kantonalbank. This financial boost, alongside increased support from main shareholder Draupnir Holding B.V., enhances PolyPeptide’s financial flexibility to pursue growth, aiming to double its 2023 revenues by 2028, particularly in the metabolic diseases and GLP-1 sectors.
The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF33.50 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.
At the fourth ordinary General Meeting, PolyPeptide Group AG’s shareholders approved all Board of Directors’ proposals, including re-elections and the introduction of new authorized and conditional share capital. These decisions are expected to strengthen the company’s financial structure and governance, potentially enhancing its market position and stakeholder confidence.